Can existing COVID drug beat dengue? new trial begins

NCT ID NCT06551844

Recruiting now Disease control Sponsor: Oxford University Clinical Research Unit, Vietnam Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing two antivirals—molnupiravir (used for COVID-19) and a lab-made antibody called VIS513—in 500 people with early dengue. Participants must have had fever for less than 48 hours and a positive rapid test. The goal is to see if these drugs can clear the dengue virus faster and reduce symptoms, while also checking for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: molnupiravir (an antiviral drug) and VIS513 (a monoclonal antibody)
What this could lead to: If successful, this could point toward a treatment that shortens dengue illness and reduces severe complications.
What could go wrong: This is an early phase 2 trial with only 500 participants, so results may not apply to all dengue patients. The drugs may not speed up recovery or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTIVIRAL DRUGS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dengue disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTIVIRAL DRUGS DENGUE

Contacts and locations

Locations

Hospital for Tropical Diseases, Ho Chi Minh city
RECRUITING

Ho Chi Minh City, 700000, Vietnam
Universiti Malaya Medical Centre
NOT_YET_RECRUITING

Kuala Lumpur, 59100, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.